Altimmune Fundamentals

ALT
 Stock
  

USD 9.46  0.41  4.53%   

Altimmune fundamentals help investors to digest information that contributes to Altimmune's financial success or failures. It also enables traders to predict the movement of Altimmune Stock. The fundamental analysis module provides a way to measure Altimmune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Altimmune stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Altimmune Gross Profit is comparatively stable at the moment as compared to the past year. Altimmune reported Gross Profit of 4.41 Million in 2021. Interest Expense is likely to gain to 5,805 in 2022, whereas Net Income is likely to drop (99.6 M) in 2022.

Altimmune EBITDA Analysis

Altimmune's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Altimmune Earnings Before Interest Taxes and Depreciation Amortization EBITDA

(99.44 Million)

EBITDA 
 = 
Revenue 
-  
Basic Expenses 
More About EBITDA | All Equity Analysis

Current Altimmune EBITDA

    
  (92.3 M)  
Most of Altimmune's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Altimmune is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Altimmune EBITDA Historical Pattern

Today, most investors in Altimmune Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Altimmune's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's ebitda growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Altimmune ebitda as a starting point in their analysis.
   Altimmune EBITDA   
Share
       Timeline  
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Compare to competition

Altimmune EBITDA Margin

EBITDA Margin

(37.6)

Altimmune EBITDA Margin is comparatively stable at the moment as compared to the past year. Altimmune reported EBITDA Margin of -34.85 in 2021
According to the company disclosure, Altimmune reported earnings before interest,tax, depreciation and amortization of (92.3 Million). This is 110.52% lower than that of the iShares sector and 192.16% lower than that of the Market Neutral industry. The ebitda for all United States stocks is 102.37% higher than that of the company.

Altimmune Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Altimmune's current stock value. Our valuation model uses many indicators to compare Altimmune value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Altimmune competition to find correlations between indicators driving Altimmune's intrinsic value. More Info.
Altimmune is number one stock in market capitalization category among related companies. It is number one stock in net income category among related companies . Altimmune Market Capitalization is comparatively stable at the moment as compared to the past year. Altimmune reported Market Capitalization of 364.01 Million in 2021. Comparative valuation analysis is a catch-all model that can be used if you cannot value Altimmune by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Altimmune's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Altimmune's earnings, one of the primary drivers of an investment's value.

Altimmune Earnings Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Altimmune's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Altimmune could also be used in its relative valuation, which is a method of valuing Altimmune by comparing valuation metrics of similar companies.
Altimmune is currently under evaluation in earnings per share category among related companies.

Altimmune Current Valuation Drivers

We derive many important indicators used in calculating different scores of Altimmune from analyzing Altimmune's financial statements. These drivers represent accounts that assess Altimmune's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Altimmune's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(1.55 M)(1.45 M)(820.8 K)(1.14 M)(2.07 M)(2.12 M)
Revenue Per Employee357.94 K382.64 K232.06 K189.83 K93.84 K96.31 K
Average Assets62.24 M55.15 M59.45 M158.72 M244.32 M263.61 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(51.87 M)(45.03 M)(21.18 M)(54.52 M)(96.89 M)(99.44 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(51.76 M)(44.72 M)(20.19 M)(54.02 M)(96.53 M)(99.07 M)
Earnings before Tax(52.06 M)(45.32 M)(20.58 M)(54.46 M)(97.09 M)(99.65 M)
Average Equity45.56 M41.09 M52.61 M136.75 M224.03 M241.72 M
Enterprise Value14.64 M11.5 M18.09 M229.51 M189.11 M151.82 M
Free Cash Flow(20.37 M)(10.39 M)(9.6 M)(34.51 M)(90.36 M)(92.73 M)
Invested Capital8.21 M2.09 M28.41 M104.32 M(2.17 M)(2.22 M)
Invested Capital Average4.58 M3.32 M16.28 M54.88 M45.09 M48.65 M
Market Capitalization31.15 M18.04 M28.99 M373.04 M364.01 M392.74 M
Tangible Asset Value24.31 M40.9 M41.33 M232.29 M206.45 M222.74 M
Working Capital19.63 M34.84 M35.47 M218.24 M185.85 M200.52 M

Fund Asset Allocation for Altimmune

The fund invests 21.57% of asset under management in tradable equity instruments, with the rest of investments concentrated in bonds (15.26%) and various exotic instruments.
   Value   
       Instrument Type  

Altimmune Fundamentals

About Altimmune Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Altimmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Altimmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Altimmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Deferred Revenue17.8 K18.2 K
Revenues4.4 M4.5 M
Revenue to Assets 0.020151  0.0207 
Revenue Per Employee93.8 K96.3 K

Altimmune Investors Sentiment

The influence of Altimmune's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Altimmune. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Altimmune's public news can be used to forecast risks associated with investment in Altimmune. The trend in average sentiment can be used to explain how an investor holding Altimmune can time the market purely based on public headlines and social activities around Altimmune. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Altimmune's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Altimmune's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Altimmune's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Altimmune.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Altimmune in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Altimmune's short interest history, or implied volatility extrapolated from Altimmune options trading.

Pair Trading with Altimmune

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altimmune will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Altimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altimmune to buy it.
The correlation of Altimmune is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Altimmune Piotroski F Score and Altimmune Altman Z Score analysis. You can also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for analysis

When running Altimmune price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
447.8 M
Quarterly Revenue Growth YOY
(0.99) 
Return On Assets
(0.23) 
Return On Equity
(0.42) 
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine Altimmune value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.